Worth Venture Partners’s Biogen BIIB Stock Holding History

Worth Venture Partners’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-15,800	Closed	-$3.73M	–	102
2019 Q1	$3.73M	Buy	+15,800	New	+$4.98M	2.08%	12

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Worth Venture Partners's BIIB Position: Q2 2019 in Review

Worth Venture Partners sold out of Biogen (BIIB) in Q2 2019, closing a stake of 15,800 shares — an estimated $3.73M sold.

Worth Venture Partners first reported a position in BIIB in Q1 2019 and held it in 1 quarter. The position peaked at $3.73M in Q1 2019. 1,010 funds tracked by Wall St. Rank hold BIIB as of Q2 2019.

Worth Venture Partners reported no remaining Biogen position as of Q2 2019 after selling out during the quarter.
Worth Venture Partners sold 15,800 Biogen shares in Q2 2019, an estimated $3.73M.
Worth Venture Partners first reported a position in Biogen in Q1 2019 and held it in 1 quarter.
Worth Venture Partners's Biogen position peaked at $3.73M in Q1 2019.
1,010 funds tracked by Wall St. Rank held Biogen as of Q2 2019.

Based on Worth Venture Partners's 13F filing for Q2 2019, filed 14 Aug 2019.